Improve Your Patients’ Satisfaction
Patients are looking for new techniques that can deliver relief from their debilitating varicose vein symptoms. Let them know that there’s a way to regain their routine and confidence—quickly and nearly painless.1
25% of patients don't seek
varicose vein treatment
over fear of pain.2
A More Comfortable Experience
Offer your patients a gentle way to treat their varicose veins. Varithena uses just 1–2 needle sticks per treatment. You can also lower their chances of complications, since your patients don’t need to take on risks associated with surgery and general anesthesia.
The Significance of Symptoms
Varicose veins are more than a cosmetic issue for patients who find themselves battling physical symptoms, like ankle swelling and leg cramps, and misconceptions about the toll it takes on their lives.
- Studies show that the general public largely perceives varicose veins as a cosmetic rather than a medical issue—and that non-specialist physicians consider varicose vein symptoms to be minor.3-4
- Research shows that patients elect varicose vein treatment solely or primarily for symptom relief, and only secondarily for cosmetic reasons.5-7
“I sleep with two pillows up under my feet to help with the pain and the radiating fire sensation.”
“I can’t walk because that hurts. And can’t really exercise.”
“I’ve always been very active. I was a tennis player. I was ballet dancer. And now I feel like all this is taken away.”
“People think you’re unhealthy, they think you’re old, they think you’re lots of stuff because you got those ugly veins.”
Results That Please Your Patients
“The improvement was like going from night to day.”
— 58-year-old man treated with Varithena
Thurman’s veins stuck out in his thigh and lower leg and would hurt at night, making it hard to sleep. Aching and pain prevented him from doing what he wanted to do. But he didn’t want to have his veins “stripped” so he delayed treatment and suffered with the pain and immobility—until he had them treated with Varithena.
- Patients reporting pain at injection or application site in clinical trials was 4.0%. BSC data on file.
- Todd KL III, Wright DI, and the VANISH-2 Investigator Group. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology. 2014;29(9):608-618. doi:10.1177/0268355513497709.
- Mason H, Baker R, Donaldson C. Understanding public preferences for prioritizing health care interventions in England: does the type of health gain matter? J Health Serv Res Policy. 2011;16(2):81-89.
- Lindsey B, Campbell WB. Rationing of treatment for varicose veins and use of new treatment methods: a survey of practice in the United Kingdom. Eur J Vasc Endovasc. 2006;32(4):472.
- O'Leary DP, Chester JF, Jones SM. Management of varicose veins according to reason for presentation. Ann R Coll Surg Engl. 1996;78(3 (Pt 1)):214-216.
- Darvall KA, Bate GR, Sam RC, Adam DJ, Silverman SH, Bradbury AW. Patients' expectations before and satisfaction after ultrasound guided foam sclerotherapy for varicose veins. Eur J Vasc Endovasc Surg. 2009;38(5):642-647.
- Palfreyman SJ, Drewery-Carter K, Rigby K, Michaels JA, Tod AM. Varicose veins: a qualitative study to explore expectations and reasons for seeking treatment. J Clin Nurs. 2004;13(3):332-340.
Varithena® (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena® improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
Important Safety Information
The use of Varithena® is contraindicated in patients with known allergy to polidocanol and those with acute thromboembolic disease. Severe allergic reactions have been reported following administration of liquid polidocanol, including anaphylactic reactions, some of them fatal. Observe patients for at least 10 minutes following injection and be prepared to treat anaphylaxis appropriately. Intra-arterial injection or extravasation of polidocanol can cause severe necrosis, ischemia or gangrene. Patients with underlying arterial disease may be at increased risk for tissue ischemia. If intra-arterial injection of polidocanol occurs, consult a vascular surgeon immediately.Varithena® can cause venous thrombosis. Follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization, or pregnancy are at increased risk for developing thrombosis. The most common adverse events observed were pain/discomfort in extremity, retained coagulum, injection site hematoma or pain, common femoral vein thrombus extension, superficial thrombophlebitis, and deep vein thrombosis.Physicians administering Varithena® must be experienced with venous procedures, possess a detailed working knowledge of the use of the duplex ultrasound in venous disease and be trained in the administration of Varithena®.
See Full Prescribing Information for Varithena®